MINNEAPOLIS, Nov. 17, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of First-Party (Direct-from-Source) regulatory decision-grade, AI-driven Real-World Data (RWD), announced financial results for the third quarter ended September 30, 2026, as reported in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, and reiterates its revenue guidance for the fourth quarter of 2026. The Co
MINNEAPOLIS, Nov. 09, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading...
First party, direct-from-source Real World Data will feed the Company’s tenth channel partner’s AI models and a licensable derivative dataset that partner will sellMINNEAPOLIS, Sept. 30, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) ("OneMedNet," the "Company," "we," "us" or "our"), a leading provider of First-Party (Direct-from-Source) regulatory decision-grade, AI-driven Real World Data (RWD), today announced a seven figure multiyear agreement to deliver de-identified, multimod
OneMedNet (ONMD) said Friday it will implement a 1-for-10 reverse split of its stock to bring the fi
MINNEAPOLIS, Sept. 25, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “Company,” “we,” or “our”), a leading provider of first-party (direct-from-source) regulatory decision-grade, AI-driven Real-World Data (RWD), today announced that it will implement a 1-for-10 reverse stock split of its issued and outstanding shares of common stock (the “Reverse Stock Split”), effective at 12:01 a.m. Eastern Time on September 29, 2026. The Reverse Stock Split was approved by the Company’s s
Customer selects OneMedNet for the full-fidelity studies and regulatory decision-grade quality required to develop AI models that accelerate drug developmentMINNEAPOLIS, Aug. 31, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of first-party (direct-from-source) regulatory decision-grade, AI-driven Real-World Data (RWD), today announced a new agreement to deliver de-identified, full-fidelity clinical Real-World D
This is the newest page. Registered accounts read further back.